Home > Formulary : Adult > Recent Decisions > 2012 >
Decisions 2nd October 2012
At the meeting on 2nd October 2012 the following additions/changes to the formulary were agreed:
Fidaxomicin
- Approved, TLS Red for patients who have suffered a relapse of C. difficile infection, or for those patients with a first C. difficile infection who are taking concurrent antibiotics which they cannot stop.
Cinacalcet
- Approved for use at NBT in addition to UHB, TLS Red for the treatment of hypercalcaemia in primary hyperparathyroidism.
Evicel®
- Approved for use at NBT in addition to UHB, TLS Red. A surgical glue.
Pigmanorm®
- Approved for the treatment of melasma, TLS Red, for Consultant Dermatologist use only.
Mesalazine (Octasa®)
- Approved, as our first line Mesalazine brand for new uncomplicated patients (400mg and 800mg tablets), TLS Green. Mezevant® XL and Mesren® to be removed from formulary
Perampanel (Fycompa®)
- Approved for the adjunctive treatment in the management of partial onset seizures with or without secondary generalisation, TLS Red
Amantadine in MS
- Approved for the use in MS patients with fatigue, TLS amber.
Tobramycin (TOBI Podhaler®)
- Deferred until results of contract price negotiation on nebulised tobramycin is known
Argatroban
- Approved as the recommended choice for the treatment of heparin induced thrombocytopenina, TLS Red. Danaparoid is now an alternative and Lepirudin removed.
Ulipristal (Esmya®)
- Approved for the treatment of uterine firboids, TLS Red
New/updated Shared Care Protocols
- Disease Modifying Antirheumatic drugs - Azathioprine, Leflunomide, Methotrexate, Sodium aurothiomalate, Penicillamine, Hydroxychloroquine. All updated.
- Acamprosate
- Valproic acid
- Colistimethate for the use in chronic respiratory patients (adult non-Cystic Fibrosis)
- Hepatitis B vaccination in renal patients
- Stalevo®
- Ropinirole
- Lanthanum
- Naltrexone for alcohol withdrawl (TLS Change from Red to amber)
- Naltrexone for opioid withdrawl
Other decisions/changes
- Tafluprost added (for patients who need preservative free eye drops in the treatment of glaucoma)
- Ivabradine license extension for use in patients with heart failure